Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at different doses of aspirin to prevent cancer in people who have Lynch syndrome (CaPP3)
This trial is comparing 3 different doses of aspirin as a way of stopping cancer developing in people who have Lynch syndrome.
Cancer Research UK supports this trial.
More about this trial
A trial called CAPP2 showed that aspirin reduces the risk of cancer in people with Lynch syndrome. But in a small number of people, aspirin can cause bleeding in the stomach. This happens more often when people take higher doses of aspirin. So researchers want to see if lower doses of aspirin work as well.
The aim of this trial is to find the best dose of aspirin that people with Lynch syndrome should take to prevent cancer.
Who can enter
You may be able to join this trial if all of the following apply. You
- Have Lynch syndrome (HNPCC)
- Are able to swallow tablets
- Are at least 18 years old
You cannot join this trial if any of these apply. You
- Regularly take a non steroidal anti inflammatory drug. For example you have had 3 doses a week, for more than 3 months in the last 3 years
- Have taken 150 mg or more of aspirin every day for more than 3 months in the last 3 years
- Are known to be very sensitive to aspirin
- Have problems with your liver or kidneys
- Have had an ulcer in your food pipe, stomach or bowel (a peptic ulcer) in the last 3 months
- Have an increased risk of bleeding or take drugs to thin your blood (anticoagulants)
- Joined the CAPP2 trial within the last 10 years
- Have any other medical condition that could affect you taking part (if you have high blood pressure, you will need to have this treated before you start taking aspirin)
- Are pregnant or planning on becoming pregnant in the next 2 years
- Are breastfeeding
This is an international phase 3 trial. The researchers need about 3,000 people to take part. Everybody joining the trial will take aspirin tablets each day.
It is a randomised trial. The people taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in. For the first 2 years, you take one of the following
- 600mg of aspirin each day
- 300mg of aspirin each day
- 100mg of aspirin each day
Whatever dose of aspirin you take, the tablets will look the same, so neither you nor your doctor will know which group you are in. This is called a double blind trial.
After 2 years of treatment, everybody in the trial will then take 100mg each day until the end of the trial. The researchers expect the trial to finish in 2021.
The trial team will contact you by phone after 3 months, 6 months, a year and 18 months. They will check how you are getting on and ask some questions about your health. The phone calls should take no longer than half an hour. After 2 years of treatment, they will phone you once a year.
You can also contact your research nurse or doctor at any time if you have any problems or questions.
The trial team will look at your medical records. All the information they collect about you will be kept
You will see the trial team before you join the trial. If you agree to take part, you have a blood test. You start taking aspirin shortly afterwards. The tablets will be delivered to your home every 6 months.
You see the trial team again after 2 years and 5 years. The researchers will ask you to give more blood samples at these visits.
The most serious side effect of aspirin is bleeding. Other possible side effects include
- Tummy (abdominal) pain
- Feeling or being sick
- Blood in the stool or black stools
Very rarely people have an allergic reaction to aspirin. And it can sometimes make asthma worse.
It is important to remember that millions of people around the world take aspirin with very few side effects. The trial team will talk to you about all the possible risks before you agree to join.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Sir John Burn
Bayer Pharma AG
Cancer Research UK
NIHR Clinical Research Network: Genetics
Newcastle upon Tyne Hospitals NHS Foundation Trust